醫藥品·生物科技的資產收購交易 (2016～2024年)

Asset Purchase Deals in Pharmaceuticals and Biotechnology 2016-2024

出版日期: 2024年03月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球醫藥品·生物科技的各種資產 (事業資產，產品資產，特許權資產，技術資產) 的收購交易的締結狀況相關分析，彙整整體交易數量·交易額的轉變和預測 (2016～2024年)，近幾年的代表性交易案例，主要企業的交易締結動向，各技術·各治療領域達成交易的動向等資訊，為您概述為以下內容。

簡介
資產收購交易定義
資產收購交易趨勢 (2016年以後)
- 資產收購交易趨勢:各年度 (2016～2024年)
- 資產收購交易趨勢:各開發階段 (2016～2024年)
- 資產收購交易趨勢:各產業領域 (2016～2024年)
- 資產收購交易趨勢:各治療領域 (2016～2024年)
- 資產收購交易趨勢:各技術種類 (2016～2024年)
- 資產收購交易趨勢:最活躍的企業的情況 (2016～2024年)
簽訂資產收購的聯盟交易的理由
- 事業資產
- 產品資產
- 特許權資產
- 技術資產
資產收購交易的未來性

第3章資產收購交易結構:概要

簡介
資產收購契約結構

第4章資產收購的主要的交易

簡介
前幾名的資產收購交易 (以金額為準)

第5章資產收購交易:最活躍的交易締結25企業

簡介
資產收購交易:最活躍的交易締結25企業

第6章資產收購交易:契約的明細

簡介
資產收購契約 (2016～2024年)
交易明細
交易明細:資產收購的交易締結，企業名 (A～Z)
交易明細:資產收購的交易締結，各治療領域
交易明細:資產收購的交易締結，各技術種類

關於Wildwood Ventures

簡介目錄

Product Code: CP2054

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

Business assets
Product assets
Royalty assets
Technology assets
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of asset purchase deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of asset purchase deals.
Chapter 4 provides a review of the leading asset purchase deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
The deal directory includes a comprehensive listing of all asset purchase deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Key benefits

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

Understand deal trends since 2016
Browse asset purchase deals
Benchmark analysis - identify market value of transactions
Financials - headline, upfront, milestone, royalty rates
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Asset Purchase Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals and Biotechnology includes:

Trends in asset purchase dealmaking in the biopharma industry
Overview of asset purchase deal structure
Directory of asset purchase deal records covering pharmaceutical and biotechnology
The leading asset purchase deals by value
Most active asset purchase dealmakers
The leading asset purchase partnering resources

In Asset Purchase Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the rights granted or optioned?
What rights are granted by the agreement?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are intellectual property rights handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

2.1. Introduction
2.2. Types of assets purchased
2.3. Trends in asset purchase deals since 2016
- 2.3.1. Asset purchase dealmaking by year, 2016-2024
- 2.3.2. Asset purchase dealmaking by phase of development, 2016-2024
- 2.3.3. Asset purchase dealmaking by industry sector, 2016-2024
- 2.3.4. Asset purchase dealmaking by therapy area, 2016-2024
- 2.3.5. Asset purchase dealmaking by technology type, 2016-2024
- 2.3.6. Asset purchase dealmaking by most active company, 2016-2024
2.4. Reasons for entering into asset purchase partnering deals
- 2.4.1. Business assets
- 2.4.2. Product assets
- 2.4.3. Royalty assets
- 2.4.4. Technology assets
2.5. The future of asset purchase deals